Drug Profile
CX 904
Alternative Names: AMG-651; CX-904; EGFRxCD3 bispecific monoclonal antibody - Amgen/CytomX; EGFRxCD3 bispecific Probody - Amgen/CytomXLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Amgen; CytomX Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours